

AGENDA

- A. Disease Specific Baseline Reporting
- B. High Cost Claims Review
- C. UHC Administrative Renewal for Plan Year 2021
- D. Virgin Pulse Proposal Overview and Implementation
 Timeline
- E. Web-Based Enrollment System RFP






PLAN SUMMARY

2019

	2018	2019	% Change
Avg Employees	1,395	1,467	5%
Avg Members	3,163	3,302	4%
Member Avg Age	31	31	
Member % Male	49%	49%	
Facility Paid	\$5.7M	\$7.0M	23%
Professional Paid	\$5.9M	\$5.7M	-3%
Medical Paid	\$11.6M	\$12.7M	10%
Rx Paid	\$4.8M	\$4.7M	-2%
Total Paid	\$16.4M	\$17.4M	6%
Out of Pocket	\$3.3M	\$3.2M	-3%
Facility Paid PEPM	\$339	\$396	17%
Professional Paid PEPM	\$352	\$325	-8%
Medical Paid PEPM	\$691	\$721	4%
Rx Paid PEPM	\$287	\$268	-6%
Total Paid PEPM	\$978	\$989	1%
Out of Pocket PEPM	\$196	\$180	-8%








Paid Jan-Dec 2018, Jan-Dec 2019

Next Generation Analysis



Disease-Specific Baseline Reporting

Episodes of care with a start date from January – December 2019 Includes complete episodes of care only Children under age 18 and retirees (if applicable) are excluded



DISEASE STAGES

Stage 3

Disease involving multiple sites, systemic complications, poor prognosis

Stage 2

Disease with localized complications

Stage 1

Disease without complications or of minimal severity

Stage 0

Leading indicators suggest that this population is at risk to develop disease



DISEASE-SPECIFIC FOCUS



246 **Patients**

\$1.4M **Direct Cost Medical**

\$441K

\$7,660

\$2.4M

Direct Cost Rx **Direct Cost PPPY Indirect Cost**



CARDIOVASCULAR CANCER

MENTAL HEALTH MUSCULOSKELETAL DIABETES

465 **Patients**

\$1.0M **Direct Cost Medical** \$180K

\$2,615

\$4.1M

Direct Cost Rx **Direct Cost PPPY Indirect Cost**



186 **Patients**

\$194K **Direct Cost Medical**

\$988K Direct Cost Rx

\$6,354 **Direct Cost PPPY** \$2.4M

Indirect Cost



743

\$1.5M

\$498K

\$2,649

\$5.2M

Patients

Direct Cost Medical

Direct Cost Rx

Direct Cost PPPY

Indirect Cost

285

\$183K

\$76K

\$909

\$2.2M



Patients

Direct Cost Medical

Direct Cost Rx

Direct Cost PPPY

Indirect Cost



DISEASE-SPECIFIC BENCHMARKING

		PREVALENCE	BENCHMARK*	DIRECT COST PPPY	BENCHMARK*
AR CANCER		10%	10%	\$7,660	\$6,983
CARDIOVASCULAR		20%	18%	\$2,615	\$3,009
AL DIABETES		8%	6%	\$6,354	\$4,649
MUSCULOSKELETAL	NA STATE OF THE PARTY OF THE PA	31%	30%	\$2,649	\$2,783
MENTAL HEALTH	6	12%	9%	\$909	\$1,183
MEN		*Hol The information o	mes Murphy & Associate on this page is proprietary. Please © 2020 HOLMES MURPHY	e do not copy or distribute to others.	



DISEASE-SPECIFIC YEAR OVER YEAR

2018

2019



12% \$9,718

Prevalence Direct Cost PPPY

10% \$7,660

Prevalence Direct Cost PPPY

99% of episodes are complete



22%

\$2,852

Prevalence Direct Cost PPPY

20%

\$2,615

Prevalence Direct Cost PPPY

99% of episodes are complete



8%

\$6,560

Prevalence Direct Cost PPPY

8%

\$6,354

Prevalence Direct Cost PPPY

99% of episodes are complete



32%

\$3,288

Prevalence Direct Cost PPPY

31%

\$2,649

Prevalence

Direct Cost PPPY

96% of episodes are complete



14%

\$1,611

Prevalence Direct Cost PPPY

12%

\$909

Prevalence

Direct Cost PPPY

76% of episodes are complete



HOW DISEASES ARE CONNECTED

	PATIENTS	DIRECT COST PPPY	DIRECT COST
	465	\$2,615	\$1.2M
	186	\$6,354	\$1.2M
	743	\$2,649	\$2.0M
& (a)	70	\$10,225	\$716K
&	185	\$6,604	\$1.2M
&	67	\$8,932	\$598K
& Q & <u>*</u>	33	\$12,021	\$397K



HOW MENTAL HEALTH IS CONNECTED



246 \$7,660 Patients Direct Cost PPPY



465 \$2,615 Patients Direct Cost PPPY




186 \$6,354
Patients Direct Cost PPPY



743 \$2,649
Patients Direct Cost PPPY




285 \$909
Patients Direct Cost PPPY







DISEASE-SPECIFIC FOCUS BY RELATIONSHIP




EMPLOYEE

SPOUSE

DEPENDENT (18+)




LEADING INDICATORS STAGE 0





BACK PAIN







DISEASE SUMMARY



High Cost Claims driving overall cost
Large number of Impactable Cancers
Above Benchmark in Cancer Screenings
Continue Focus on Targeted Age & Gender Screenings



Stage 0 & 1 Above Benchmark
Hypertension impacting multiple stages & other diseases
Focus on Leading Indicators to Avoid Disease - Implement MetS Program
Consider Hypertension Management Program in future



Above Benchmark in Cost Per Patient Per Year
Largest population at risk for developing disease
Type 2 Diabetes with Vascular Disease most common diagnosis
Consider Diabetes Management in future



Highest number of patients in Stage 1
Joint Disorders & Low Back Pain most common diagnosis
Back Pain impacting Mental Health
Consider Physical Therapy Program in future (Virtual or In Person)



Showing Year over Year Improvement in reducing severity of disease

Depression impacting multiple stages & other diseases

Anxiety and Depression is most common diagnosis

Focus on programs for Stress Management



POTENTIAL STRATEGIES SUMMARY

Disease- Specific Focus	Best Practice	Desired Behaviors	Engagement Offer → Incentivize → Require	Solutions
	Wellness Portal	Personalized Action Plans to Avoid & Reduce Disease	Incentivize Activities	Rally VirginPulse
2 00- 10-11	Metabolic Syndrome Program	Healthy Weight In Range Lab Values	Offer program	Naturally Slim Blue Mesa
*	Stress Management Program	Resiliency Anxiety Reduction Depression Reduction	Offer program	Joyages with Talkspace
	Hypertension & Diabetes Management Program	Medication Management & Reversal of Disease	Offer program	Livongo OneDrop
Sec. Sec. Sec. Sec.	Physical Therapy	Increase Movement & Flexibility Pain Reduction	Offer program	HingeHealth Airrosti

NEXT STEPS

For the greatest impact within your employee population:

Launch Wellness Portal

Hub of Information to focus on both Avoiding & Reducing Disease

Implement MetS Program

Obesity & Hypertension are Leading Indicators and diagnoses for Multiple Diseases

Implement Diabetes Management Program

Pharmacy Spend and Cost above benchmark





DIABETES Don't Sugar Coat It





DIABETES OVERVIEW

DIABETES MELLITUS (DM)

Type 1: Not limited to being a childhood disease; body does not produce insulin

Type 2: Most common; body does not respond to or make enough insulin

Approximately 45% of US adults have Prediabetes or Diabetes

BENCHMARK*

WILCO: 8%

HMA: 6%

Patients in Stage 0 #1 of 5 diseases

1,149

Direct/Indirect PPPY #1 of 5 diseases

\$19,148

IMPACTABLE

Type 2

DIFFICULT TO IMPACT

Type 1






DIABETES STAGES







DIABETES STAGES BENCHMARKING



Patients in Stage 0:

Patients in Stages 1-3

Williamson County **6.2**: 1.0


Benchmark* 6.2: 1.0






DIABETES STAGES YEAR OVER YEAR CHANGE

Cohort of patients with a Diabetes episode in 2018 & 2019









DIABETES STAGE 0

HYPERTENSION*

411
Patients

2.5 times more likely to develop
Diabetes

OBESITY*

359
Patients

Single biggest predictor of Type 2
Diabetes

NEUROPATHY

41Patients

1.75 times more likely to develop
Diabetes

SLEEP APNEA

113
Patients


1.63 times more likely to develop
Diabetes





DIABETES STAGE 1

% of Cost



Top Episodes by Total Cost	Total Cost	Patients
Symptomatic DM Type 2	\$135,210	14
Asymptomatic DM Type 2	\$96,864	34
Symptomatic DM Type 1	\$26,906	3
DM Type 1	\$19,218	2
Impaired glucose tolerance	\$17,698	19

% of Episodes




Top Episodes by Patients	Total Cost	Patients
Asymptomatic DM Type 2	\$96,864	34
Impaired glucose tolerance	\$17,698	19
Impaired fasting glucose	\$2,780	15
Symptomatic DM Type 2	\$135,210	14
Symptomatic DM Type 1	\$26,906	3






DIABETES STAGES 2 & 3

% of Cost



Top Episodes by Total Cost	Total Cost	Patients
DM Type 2 with vascular disease	\$671,718	89
DM with sepsis	\$70,145	2
DM Type 1 with retinopathy	\$61,962	3

% of Episodes




Top Episodes by Patients	Total Cost	Patients
DM Type 2 with vascular disease	\$671,718	89
DM Type 1 with retinopathy	\$61,962	3
DM with sepsis	\$70,145	2





POTENTIAL STRATEGIES








Appendix





HIGH COST CLAIMS REVIEW

UnitedHealthcare



High Dollar Claim Diagnosis Report

Customer: Williamson County Renewal: 1/1/2021

Note: This Large Loss Report is to only be released after Contracts has received all signed documentation.

Claimant 1 Claimant 2

Paid Amount: \$ 1,045,715.78 Paid Amount: \$ 808,335.07 Status: Ongoing Status: Closed Diagnosis: Mega Colon, Fistulas Diagnosis: Expired

Claimant 3 Claimant 4

Paid Amount: \$ 749,815.13 Paid Amount: \$ 363,219.90 Status: Ongoing Status: Closed Diagnosis: Castleman's Disease Diagnosis: Expired

Claimant 5 Claimant 6

Paid Amount: \$ 354,238.20 Paid Amount: \$ 347,416.62 Status: Ongoing Status: Ongoing

Diagnosis: Chronic Lymphocytic Leukemia Diagnosis: Acute Myeloblastic Leukemia

Claimant 7 Claimant 8

Paid Amount:\$ 347,278.13Paid Amount:\$ 280,084.47Status:ClosedStatus:OngoingDiagnosis:TermedDiagnosis:Multiple Myeloma



UHC ADMINISTRATIVE RENEWAL

2021 Renewal Terms

- Individual Stop Loss +8%, Aggregate Stop Loss -8.8%,
 Overall Stop Loss Increase: +4.4%
- 2. Medical Administrative Fee: +1.1%
- 3. Dental Administrative Fee: +0%
- 4. Vision Premiums: +0%
- 5. Flexible Spending Account Fee: +0%



VIRGIN PULSE PROPOSAL

Discuss Proposal (see supporting documents)

- 1. Overview
- 2. Pricing
- 3. Timeline



WEB-BASED ENROLLMENT SYSTEM RFP

Discuss RFP (see supporting documents)

- 1. Overview
- 2. RFP elements
- 3. Discus Timeline

